- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01901562
Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge
In this prospective clinical trial, patients who sign an approved informed consent for ductoscopy to assess etiology of Pathologic nipple discharge (PND) will be enrolled in the study. Consented patients who have been diagnosed with a solitary papilloma within the discharging duct will be recruited to have interventional ductoscopy.
Patients who are identified ductoscopically with a solitary non-sessile papilloma will undergo an attempted ductoscopic papillectomy (DP). Patients with ductoscopic findings other than single non-sessile papilloma will undergo standard ductoscopically guided microductectomy. The investigators will investigate whether the ductoscopic basket can be used as a safe endoscopic extraction instrument without adverse events. Histopathological evaluation will be performed to confirm the ductoscopic diagnosis and to determine the existence of any malignant tissue.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be female
- Have pathologic (unilateral/uniductal) nipple discharge
- Been diagnosed with single papilloma
- Be over 18 years of age
- Sign the informed consent form
Exclusion Criteria:
- Have bilateral nipple discharge
- Personal history of breast cancer, ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)
- Have BRCA 1 or 2 mutation
- Be currently pregnant or pregnant within the last 12 months
- Be currently lactating or lactated within the last 12 months
- Have received chemotherapy in the last 12 months
- Have had a Breast Imaging-Reporting and Data System (BIRADS) 3, 4, 5 or 6 mammograms within the last year
- Have diagnosed with multiple or sessile papilloma by ultrasound, mammography and/or ductoscopy.
- Have suspicious of malignancy in ultrasound
- Have an abnormal finding on the pre-operative nipple smear
- Have Gail Score >1.67
- Have had any subareolar or other surgery
- Have active infections or inflammation in a breast to be studied
- Have a known allergy to lidocaine
- Have abnormal liver function test
- Have medications know to be associated with breast discharge.
- Be unable to attend postoperative visits and imaging work-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ductoscopic papillectomy
Ductoscopic papillectomy to treat pathological nipple discharge
|
Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Complete Ductoscopic Retrievals
Time Frame: 6 months
|
Technical success will be determined by complete (total ductoscopic retrieval of a papilloma) ductoscopic retrieval of lesions over 90% of enrolled patients diagnosed with solitary papilloma.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Cessation of Nipple Discharge
Time Frame: Up to 2 weeks from the procedure
|
Therapeutic success will be determined by cessation after ductoscopic papillectomy (DP) in over 95% of enrolled patients with pathologic nipple discharge (PND) with a single papilloma.
|
Up to 2 weeks from the procedure
|
Number of Patients With Clinical Recurrence of Nipple Discharge
Time Frame: Up to 2 years
|
Patients will be monitored for recurrence of nipple discharge at 6 month intervals for 2 years.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sheldon Feldman, MD, Montefiore Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Pregnancy Complications
- Puerperal Disorders
- Neoplasms, Squamous Cell
- Neoplasms, Ductal, Lobular, and Medullary
- Lactation Disorders
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Papilloma
- Papilloma, Intraductal
- Galactorrhea
Other Study ID Numbers
- AAAK3900
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Discharge Infected
-
Mayo ClinicCompletedBreast Cancer | Bloody Nipple DischargeUnited States
-
Assiut UniversityUnknownContrast Mammography in Pathological Nipple Discharge
-
Duke UniversityCompletedDrug Related Problems Post Hospital Discharge | Healthcare Utilization | Discharge Medication CounselingUnited States
-
Mayo ClinicCompleted
-
Hackensack Meridian HealthWithdrawn
-
C.O.C. Farmaceutici S.r.l.Completed
-
Virginia MoyerAgency for Healthcare Research and Quality (AHRQ)CompletedPatient DischargeUnited States
-
Boston Medical CenterRecruiting
-
Cambridge Health AllianceCompletedPatient DischargeUnited States
-
Medical College of WisconsinUniversity of Wisconsin, Milwaukee; Children's Hospital and Health System Foundation... and other collaboratorsCompletedPatient DischargeUnited States
Clinical Trials on Ductoscopic papillectomy
-
Kliniken Ludwigsburg-Bietigheim gGmbHNot yet recruitingCholangiopancreatography, Endoscopic Retrograde
-
Azienda Unità Sanitaria Locale della RomagnaRecruitingAmpulla of Vater Adenoma | Ampullary Cancer | Ampulla of Vater Cancer | Ampullary AdenomaItaly
-
Arcispedale Santa Maria Nuova-IRCCSCompletedFamilial Adenomatous Polyposis | Ampullary Adenoma
-
Soonchunhyang University HospitalUnknownAmpulla of Vater AdenomaKorea, Republic of
-
Soon Chun Hyang UniversityCompletedAmpulla of Vater AdenomaKorea, Republic of
-
First People's Hospital of HangzhouCompletedAmpullary AdenomasChina
-
Asian Institute of Gastroenterology, IndiaNot yet recruiting